Pre-meeting Industry-supported workshop

Treatment decisions in high-risk AML*: what is the ultimate goal?

*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

5th Annual Meeting of the International Academy for Clinical Hematology (IACH)

Thursday, September 22, 2022
12:00–13:05 (CEST)

Chair: Mohamad Mohty (France)

FACULTY:

Mohamad Mohty
France

Bio

Thomas Cluzeau
France

Bio

Martin Bornhäuser
Germany

Bio

Gert Ossenkoppele
The Netherlands

Bio

Adriano Venditti
Italy

Bio

Thomas Schroeder
Germany

Bio

AGENDA:

Live welcome and introduction
Chair: Mohamad Mohty (France)
Is treatment with curative intent the ultimate goal?
Panel discussion
Thomas Cluzeau (France) and Martin Bornhauser (Germany)
Is intensive chemotherapy the antileukaemic standard of care?
Gert Ossenkoppele (The Netherlands)
How should MRD assessment inform treatment decisions?
Adriano Venditti (Italy)
Pursuing long-term survival in the real world
Thomas Schroeder (Germany)
Live Q&A and conclusions
Mohamad Mohty (France)

This promotional session funded and organised by Jazz Pharmaceuticals is intended for healthcare professionals only
Prescribing information and adverse event reporting information will be provided during the sessions.